Lv1
20 积分 2025-07-22 加入
The evolving landscape of targets for lipid lowering: from molecular mechanisms to translational implications
3天前
已完结
PCSK9-directed therapies: an update
3天前
已完结
PCSK9 inhibition with orally administered NNC0385-0434 in hypercholesterolaemia: a randomised, double-blind, placebo-controlled and active-controlled phase 2 trial
3天前
已完结
Oral PCSK9 Inhibitors: Will They Work?
6天前
已完结
AZD0780, the first oral small molecule PCSK9 inhibitor for the treatment of hypercholesterolemia: Results from a randomized, single-blind, placebo-controlled phase 1 trial
6天前
已完结
Oral PCSK9 Inhibitors
7天前
已完结
Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome
2个月前
已完结
PCSK9 and inflammation: role of shear stress, pro-inflammatory cytokines, and LOX-1
2个月前
已完结
Pharmacological rationale for the very early treatment of acute coronary syndrome with monoclonal antibodies anti-PCSK9
2个月前
已完结
PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia
2个月前
已完结
皖公网安备34019202002308
